Across TCGA pan-cancer cohorts, FAM169A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM169A data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM169A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM169A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where FAM169A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.868	0.602	.003	21	view →
PDAC	DFS	Quartile	II,III,IV	0.485	0.270	.012	11	view →
GBM	OS	Quartile	All	0.634	0.346	.002	9	view →
LUAD	DFS	Tertile	All	0.843	0.422	.010	5	view →
LSCC	OS	Median	All	0.831	0.931	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: FAM169A tumor-vs-normal RNA expression · all FAM169A data types